I wrote a commentary earlier this morning in a private

New Post Public Reply Private Reply Replies (1) Message Board
plutonium weaver_525 #7100
494
I wrote a commentary earlier this morning in a private post. But it is appropriate that I post it publicly. My earlier post is included here toward the bottom.

Since I follow this for nine years now it has never been DECN's but always someone elses'fault. Hard to believe. It contradicts any real life experience.

You bought a penny stock. These are things that happen. Stocks go up and stocks go down. The company provides 4 reports each year to investors. The reports are much more detailed than called for. Why, because your management, who you hate, are also shareholders and when the stock goes down, or when the stock goes up but not enough, management is hurt by this too. So management wants you to know why. Every dollar that comes into the company is reinvested in the company, not in management salaries. Management doesn't take salary. Management and directors do not have the time or inclination to post hate on message boards. They still have to do their jobs. So they just read the hate and work on. Their jobs are not easy, even though stock traders, flips and malcontents would make you believe otherwise. There are two major things wrong with small public companies these days. First is the left-over government and the Obamakins, the other are the entitled shareholders.

It is the reason I accepted an early retirement package. I had come to the conclusion that the USA as we know it would be gone for good (or bad) 6 months after a Hillary presidency began. The problem the Trump Admin faces is that so very many Obamakins still populate the Federal agencies. The FDA and the SEC, for example, the two agencies that I worked with the latter half of my career, are not regulatory agencies, they are propaganda implementation agencies. I know first hand how both agencies hate small business, because both agencies are convinced that small business only cares about money and do not understand that they will not have earned the money, so they have to be stopped before they start. And as everyone knows, money is not to be accumulated because of hard work and great ideas, it is to be redistributed.

A very sad commentary.

So in the end, you get what you get. And everything gotten is so richly deserved. People are different. You want a higher stock price. I worked in in-vitro diagnostics for 42 years, took two years off, and am working in the channel again. I tried for 42 years to create what KB is on the verge of bringing commercial. He has created the product of a lifetime. He has also doubled down on this product with a second product right behind it. Both products are lifetime achievements. I know this because I spent a lifetime and failed. It took me a long time to realize that sometimes in life you fail, no matter how entitled you feel you are. Perhaps KB got lucky. Perhaps he should have become a stock trader. I don't know. What I do know is that GenUltimate TBG and GenChoice TBG will take a big bite out of user bases that total 4 million in the US. But as I have said none of this matters. It is all and only about share price. And you know it.
1

Decision Diagnostics Corp (DECN) Stock Research Links

DECN Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Co-Diagnostics Nearing India TB Test Launch By 2026

Updated Category News Views 65

Co-Diagnostics Gears Up for Indian TB Test Market Picture this: Co-Diagnostics, a molecular diagnostics player, is on the brink of a significant leap toward expanding its footprint in India with its TB test. The stage is set, with a clinical study already turning in results as solid as old boots. We're talking sensitivity hovering around 97.3% and specificity at...

Continue Reading
Worldline Crowned as 2026 SPARK Matrix Leader

Updated Category News Views 68

Worldline's Journey to Leadership When you talk about the big dogs in payment services, Worldline’s name crops up for a reason. They've just snagged a top spot in the 2026 SPARK Matrix by the QKS Group, putting them in the limelight as a leader in Merchant Payment Platform technology. If you're in payments, this is worth a double take. The SPARK Matrix Breakdown The...

Continue Reading
Implantica's Strategic U.S. Entry with RefluxStop®

Updated Category News Views 50

Implantica's Ambitious Move into the U.S. Market Every now and then, a move in the medtech sector grabs everyone's attention, and that's what we got with Implantica's latest play. This company is pulling out the big guns to push its RefluxStop® device into the U.S. market—one of the toughest nuts to crack. They've roped in Dr. John C. Lipham, a leading U.S. surgeon, to...

Continue Reading
Class Action Lawsuit Hits Honor GMC & Hummer Hard

Updated Category News Views 35

Digging into the Allegations Against Honor GMC & Hummer Well, it looks like Honor GMC & Hummer is in hot water this week. The Zakay Law Group, a San Diego-based legal firm, has filed a class action complaint against the dealership giant, claiming they've been cutting corners where it matters most—paying their workers. What's the Beef? The suit levels some hefty...

Continue Reading
2026 World Laureates Forum Drives Science Forward

Updated Category News Views 69

A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...

Continue Reading
Flagstar Faces Heat: 9.2% Stock Drop Spurs Probe

Updated Category News Views 76

Flagstar's Descent: What Led to the Stock Tumble? And here we go again with a big name in finance taking a hit right between the eyes. Flagstar Bank, under ticker NYSE:FLG, saw its shares plummet by over 9.2% on October 23, 2026. This isn't just a blip—it's a spill. The backdrop here is an eye-watering $12.9 billion loan book tied to rent-regulated apartment buildings....

Continue Reading
Webull Faces Investor Lawsuit: Compliance in Question

Updated Category News Views 130

Webull's Run into Regulatory Fog Well, here we go—another tech company caught with its pants down over alleged ties with China. Webull Corporation (NASDAQ:BULL) is in the crosshairs of a class action lawsuit. Investors are sharpening their pitchforks, and you've got until December 7, 2026, to throw your hat in the ring as lead plaintiff. The Core of the Allegations...

Continue Reading
Japanese Hair Care Brand &honey Garners Top U.S. Award

Updated Category News Views 79

Hydration Reigns in Hair Care Here's something that'll make your average shampoo tremble in its plastic boots: Japan's &honey Deep Moist Shampoo has snagged the spot as Best Drugstore Shampoo for 2026, according to the Marie Claire Beauty Awards. It’s not some trivial title, folks. In a market flooded with every hair-elixir promise under the sun, getting this nod is...

Continue Reading
Baystate Health's Pilot Eases Access to Medical Services

Updated Category News Views 0

Rethinking Healthcare Access with Baystate Health Now here's a bit of news that doesn't make you wanna choke on your coffee: Baystate Health's Clear Path Pilot Program is shaking things up in the healthcare game, and it's about time. The initiative, rolling out with Health New England, is like waving a magic wand over the usual bureaucratic mess of prior authorizations....

Continue Reading
Vanda's NEREUS Outperforms in GLP-1 Vomiting Study

Updated Category News Views 32

A Surprising Breakthrough in Vomiting Prevention You don't need to be an old hand on Wall Street to see that when a biotech company rolls out positive trial results, ears perk up. Today, Vanda Pharmaceuticals' announcement that their NEREUS™ (tradipitant) drug aced Study 3601 is catching more eyes than initially expected. It's not just about hitting numbers; it's about...

Continue Reading

Top 5 Most Recently Viewed Articles

Replimune Group Faces Class Action Lawsuit Amid FDA Setback

Updated Category News Views 184

Replimune Group Faces Class Action Lawsuit Amid FDA Setback Pomerantz LLP has brought attention to a class action lawsuit involving Replimune Group, Inc. (NASDAQ: REPL). This legal action is relevant for investors who have experienced losses on their investments in the company. It's crucial for affected investors to be proactive and consider their options as they navigate...

Continue Reading
ARGAN Reports Major Carbon Emission Reductions in 2025

Updated Category News Views 323

Embracing Sustainability: ARGAN's 2025 ESG Report Highlights ARGAN, a leader in the development and rental of premium warehouses, has recently published its 2025 ESG report, showcasing remarkable achievements in sustainability and environmental stewardship. The report outlines a significant 25% reduction in CO2 emissions associated with energy consumption in their...

Continue Reading
Feedonomics Enhances YouTube Shopping With Strategic Partnership

Updated Category News Views 55

Feedonomics Partners with YouTube for Shopping Program Feedonomics has announced an exciting new partnership with YouTube that aims to boost the YouTube Shopping affiliate program. This collaboration focuses on providing robust product listing services and data optimization for merchants who participate in this rapidly growing online shopping platform. Streamlining...

Continue Reading
BJ's Wholesale Club Achieves Record High Stock Value of $92.38

Updated Category News Views 89

BJ's Wholesale Club Stock Breaks Records In an impressive show of market confidence, BJ's Wholesale Club Holdings Inc (NYSE: BJ) has celebrated a remarkable achievement as its stock surged to an all-time high, reaching a price of $92.38. This remarkable progression highlights the company’s ongoing growth and a substantial yearly change of 39.83% in stock price....

Continue Reading
Conduent's Upcoming Earnings: What Investors Should Know

Updated Category News Views 133

Conduent's Earnings Announcement Insights Conduent (NASDAQ: CNDT) will be sharing its quarterly earnings report soon. This announcement is essential for investors who are keen to understand the company's performance in detail. What Analysts Expect Analysts are currently estimating an earnings per share (EPS) of $-0.07 for Conduent. These figures are formulated based on...

Continue Reading